About AREV Life Sciences

We are a small publicly traded life science enterprise invested in commercial innovations in phytomedical discoveries of small molecule antivirals and have a significant footprint in human nutrition including the development of an RUTF for SAM and an Enteral Formula targeting the long term effects of COVID 19.

Learn More

About AREV

AREV Global Life Sciences Corp. (AREV) is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. Our strategy is dedicated to generating revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic comorbidities.

We are invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and have a significant footprint in human nutrition including the development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long term effects of COVID-19. Through our Scientific Advisory Board (SAB) and strategic collaborations with Voynich Biosciences and Oyagen, we are connected to the Linus Pauling Institute at Oregon State University (OSU) and with the Institute of Human Virology.  AREV is working with scientists at Voynich and Oyagen to serve as preclinical discovery partners for our REV inhibitor. Our SAB is reflective of industry leaders and academic collaborations.

AREV is dedicated to designing and delivering innovation in nutritional therapeutics and rational drug design, driven by molecular epidemiology. AREV’s business model is driven by leveraging its core competency of extraction to produce ingredients and compounds for its pipeline of products.

Mission Statement

We strive to innovate human and animal health solutions through phytomedicinalization and commercialization of unique botanicals and select marine species while we grow through licensing relationships, joint ventures, and acquisitions.

Corporate Values

AREV is driven by a commitment to offering novel therapeutic solutions and innovations in global public health applications that address the clinical needs of vulnerable key populations affected by pandemic diseases.

AREV believes in equitable collaborations, including mutually advantageous relationships with relevant industry partnerships, academia institutions, and civil society. AREV believes in good corporate practice:  accountability on all levels, fiscal responsibility, a commitment to shareholders, integrity, and transparency.

AREV stands in alliance with International declarations such as The Right to Health (a collaboration of the World Health Organization and Office of the United Nations High Commissioners for Human Rights), in our commitment to global citizenship by addressing issues that have a dramatic impact on infectious diseases and access to treatments in resource poor settings.

AREV is committed to ethical sourcing at all levels of our product development and research.

AREV is committed to empowerment of our staff, of the communities we work in, and to the life sciences sector.

AREV is committed to fair workplace culture. We believe it is a delicate blend of an organisation's leadership, values, traditions, beliefs, interactions, behaviours and attitudes that contribute to the emotional and relational environment of your workplace.

AREV is committed to fair practice in addressing racial and gender disparities in access to essential medicine.

AREV is committed to timely compliance with all regulatory obligations.

Community Involvement

AREV is engaged with its community. With its presence in the Rochester NY area and the connectivity via its Scientific Advisory Board, the company is perfectly positioned both geographically and politically. Rochester is close to Washington, Baltimore, Toronto and is home to the Rochester Bioventure Center. The company is a Member of BIO and Biotec Canada.

Board of Directors

Michael Withrow

Chairman, CEO

Mr. Withrow is a successful natural products and technology entrepreneur with over 25 years experience in public markets. He has an extensive business network throughout the Americas and Pacific Rim, and his experience in international trade and regulatory compliance have been essential to the companies that he has structured and led.

With a background of starting many agricultural-type companies and helping them to grow, he has worked with and led companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. Mr. Withrow has expanded his company, CanViet Enterprises Inc., internationally and met the opportunities where they resided. He was instrumental in securing millions of dollars in public and private investments to fund the working capital requirements of his high-growth companies. In addition, Mr. Withrow has also held senior advisory positions for a number of companies.

Mr. Withrow is the founder of the company and has been the Chairman of the Board of AREV since inception. He has also served as the President, CEO of Abattis Bioceuticals Corp. from 2011 – 2015. Abattis Bioceuticals Corp. a specialty cannabis company producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in the pharmaceuticals, nutraceuticals, cosmetics, and animal nutrition markets.

He also served in directorships/management positions with North American BioExtracts Inc. (2010-2015), with Canadian Pacific Phytoplankton Ltd. and Canadian Pacific Algae Inc. (2008-2010) and with BFuel Canada (2006-2007).

Kevin Phelps

CPA, Director

Mr. Kevin Phelps is a successful biotech and general business professional with over 30 years’ experience in business assessment, business development, commercialization, operations, mergers/acquisitions, capital formation, franchising and licensing.  Kevin has been a member of numerous executive teams as CEO, CFO and VP Business Development.  He has successfully managed and sold several entrepreneurial businesses and raised millions of dollars in early and growth stage capital.

Currently, Mr. Phelps is Chief Executive Officer and President of Immune Therapeutics, Inc., an OTC listed (IMUN) bio-pharmaceutical company.   He was originally recruited to Immune in November 2018 as a Director.  In April 2020 he was voted in as President and CEO.

Kevin began his career as a CPA with Price Waterhouse Coopers specializing in services to emerging growth companies.  In 1987 he was recruited to the Eastman Kodak Company and as part of an executive team successfully executed the spinout of the Bio Products Division into Genencor International, Inc., an international industrial bio-chemicals company. Mr. Phelps served as Chief Financial Officer and VP of Business Development.  In those capacities he was directly responsible for executing the formation strategy of the new Company and later the acquisition of two European chemical company competitors. 

Following Genencor, Mr. Phelps joined Trillium Group, a regional private equity firm, as a partner, during which time he underwrote and developed a portfolio of small growth companies including several in the drug development and medical device sectors.  While there he served on behalf of the firm as CFO of Vaccinex, Inc., a vaccine development company and Chairman of AccuMed, Inc., a medical device company.

Mr. Phelps graduated from the University of Notre Dame with a degree in Accounting.  He is a former CPA and has been active in Upstate New York venture capital community.  In addition to the AREV Board, he currently serves on the Boards of OyaGen, Inc. (Chairman), Immune Therapeutics, Inc., and Rochester Friendly Senior Services (Treasurer).

Denby Greenslade

Director Corporate Secretary

Ms. Greenslade has worked as a Corporate Secretary and Director for several companies in the mining, biotech and IT industries and is constantly updating her business training.

She is responsible for the creation and regulation of the Company’s corporate governance structures, policies and mechanisms; corporate communication, conduct and regulatory compliance in both Canada and the United States; Board and shareholder meetings and communication; office and personnel management; creation and administration of company policies and procedures; and implementation of corporate-wide management and document retention systems.

Ms. Greenslade has over 15 years of corporate secretarial, corporate governance,  and  securities  regulation  experience  with  a  focus  on  the nutraceutical and mining sector in Canada and Mexico. She has served in several senior management and executive roles for companies listed on the Toronto Stock Exchange, TSX Venture Exchange and Canadian Stock Exchange.


During her career, she has been involved in numerous transactions and financings, and has led the evaluation, design, implementation and monitoring of governance programs for several junior mining companies.


Ms. Greenslade graduated from Simon Fraser University, British Columbia with a Bachelor of Arts in Communication and further attended BCIT to complete an associate certificate in Graphic Design.

Frank Phillet

CPA, Director

Michael Frank Phillet is on the board of First West Properties Ltd. and APA Bioceuticals, Inc. and Partner at Phillet & Mclennan Chartered Accountants. He holds a BA, CA and CPA designation. He has been in public practice for 40 years.

Special Counsel for Corporate Development

Chad S. Johnson

Esq., Special Counsel for Corporate Development

Chad S. Johnson, Esq., is a Harvard-trained corporate, legislative, and regulatory attorney with significant experience in advising health and biotechnology companies and pursuing entrepreneurial ventures. After clerking for a federal judge, Chad joined top law firm Skadden, Arps, Slate, Meagher & Flom LLP in its Washington, DC office where he focused on financial institution regulatory law and substantial pro bono advocacy on behalf of political, civil rights, and poverty-mitigation and other civic organizations. Leaving the firm after several years to work on a presidential campaign as deputy national director of business leader outreach, he is an active member of the District of Columbia Bar and the Bar of the U.S. Supreme Court. Chad works as a business leader, board member, and legal counsel for North American and European health-related, drug-development, and biotechnology companies and non-profit organizations, with a focus on entrepreneurial ventures in biotechnology and pathogen-related treatment and mitigation. He is a member of the IAS and the Infectious Disease Society of America and has attended numerous scientific conferences internationally. Chad remains active in the Harvard College and Harvard Law School alumni associations. Originally from Kansas, Chad has lived and worked in Washington, DC and/or the DC metro area for more than 25 years.

AREV Scientific Advisory Board

AREV’s Scientific Advisory Board is composed of leading nutritional, epidemiological, and virology scientists who are highly respected as experts in their fields of expertise. Our advisory board is a strategic complement of hands-on people who are seasoned professionals who assist AREV in developing and delivering our pipeline of innovations.

Roscoe M. Moore, Jr

DVM, MPH, PhD

Dr. Moore, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms, as Chairman of the Scientific Advisory Board.  Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.


Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible for the last 12 years of his career for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service entering with the U.S. National Institutes of Health (NIH) and rising to the rank to Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.


Dr. Moore has conducted clinical research on infectious diseases, has evaluated the safety and effectiveness of medical devices, and has conducted relevant epidemiological research on the utilization experience and human health effects of medical devices and radiation. Dr. Moore served on the Fogarty International Center advisory board of directors, NIH, from 2009 to 2013. He served on the alumni board of directors for the school of public health, University of Michigan, from 1987 to 1993. Dr. Moore served on the dean's alumni council, Bloomberg School of Public Health, at Johns Hopkins University, from 1998 to 2002. He has also served as an affiliate associate professor of environmental health for the University of Washington, Seattle, from 1994 to 2003, and as an adjunct professor of epidemiology for the Medical University of Southern Africa, Pretoria, South Africa, from 1999 to 2002. He served on the board of directors for the Africa Center for Health and Human Security, at George Washington University, from 2006 to 2009.

Jay Stratton Noller

PhD

Dr. Jay Noller is a globally recognized polymath in agriculture, environmental and earth sciences, archaeology, and visual arts. He has led organizations that provide diverse activities in education, research, extension, and public service relevant to seed production, soils and ecosystem services, small farms and community food systems, integrated pest management, and various approaches to natural resource management. 


Dr. Noller has served in numerous roles as leader or administrator of enterprises that provide wheat, potatoes, and other food commodities to the world at large as well as to food systems at community level.  He is also an inventor, entrepreneur, and advisor in areas of his diverse expertise, mostly recently founding an innovative phytomedicinal and drug-discovery enterprise, Voynich Biosciences, Inc., with headquarters in Kauai, Hawaii.


Dr. Noller is a professor emeritus at Oregon State University (OSU) and is the founding director and lead researcher of OSU's Global Hemp Innovation Center (GHIC). GHIC is the world's most comprehensive research center devoted to the study of hemp, providing the most comprehensive knowledge of hemp innovation to be found anywhere. GHIC is advancing the research of hemp and its market potential across multiple diverse industries and research fields to serve the growing international demand for innovative approaches to food, health, and fiber. Dr. Noller has been Oregon's leader in hemp research and policy since 2014 and has developed research partnerships with over 40 institutions globally devoted to improving hemp genetics and modes of production and processing for fiber, grain essential oils and advances in new classes of hemp varieties. He has directed hemp research and related industrial projects across North America, China, and Europe.


Dr. Noller 's educational career includes research within the disciplines of soil science, geomorphology, art and archaeology. In addition to his hemp projects, his research principally focused on human interactions with soils in modern and ancient agricultural and forest landscapes of the Middle East, Europe and the Americas. His experience includes more than 50 large projects, spanning much of North and South America, Southern Europe, southwest Asia and Africa. He has published more than 200 papers and maps, and six books, and he has made contributions to several additional works.

Harold Smith

PhD

Dr. Harold Smith is the founder, CEO, and president of OyaGen, Inc., a biotechnology company developing therapeutics for various disease states including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.

Under Dr. Smith leadership, OyaGen has discovered and patented first-in-class lead (Irino-L) that enables innate immunity against HIV as a treatment with curative potential for HIV/AIDS and recently sold patented best-in-class Oya1 as candidate treatment for infections due to Coronavirus, Ebola virus, Lassa virus and Pox virus. In addition, Oyagen’s laboratory, platform technology, and broad technical knowhow has enabled the development of a cancer drug discovery platform based on gene editing enzymes. Oyagen is located in Rochester, New York in a state-of-the-art laboratory within the Rochester BioVenture Center. 

Robert Melamede

PhD

Dr. Robert Melamede received his doctorate degree in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes.  Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs.  He co-founded Cannabis Science, Inc., a public company, retiring as the company’s chief executive in 2014.  Dr. Melamede continues his innovative research in the private sector.

Uma Dhanabalan

MD, MPH, FAAFP, MRO, CMS

Dr. Dhanabalan advises AREV on product development and formulation.  She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts.  Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master's degree in public health from Harvard’s School of Public Health in Boston, Massachusetts and continued her training at Harvard in occupational and environmental medicine.

David Miller

PhD

Dr. David Miller is an AIDS treatment activist and skilled advocate within the biotechnology sector, working to advance the cascade of discovery and development of innovative therapeutics.  He is the former chair and current member of the Community Advisory Board of the University of Rochester Adult AIDS Clinical Trials Group (ACTG) of the NIH. He attends global health and infectious disease conferences each year, reporting key developments in the print and image media and has co-authored several peer-reviewed conference abstracts. Dr. Miller also served as co-chair of the New York City HIV Planning Council Advisory Group, which oversees the distribution of Ryan White CARE Act grants, on the Bronx HIV CARE Network, as the HIV/AIDS Treatment Education Coordinator at Health People Inc., and on the Cornell ACTG Community Advisory Board.  He is a former board member of the AIDS Institute, a leading advocacy organization for federal support of people with HIV/AIDS and their healthcare providers.  Dr. Miller was a longtime member of ACT UP NY and has participated in numerous demonstrations for access to essential life-saving medicines and nutritional supplements for people living with HIV/AIDS.